Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

194.91USD
19 Nov 2018
Change (% chg)

-- (--)
Prev Close
$194.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,128,912
52-wk High
$210.18
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.90 31.23 33.59
EPS (TTM): 11.00 -- --
ROI: 11.98 15.57 15.05
ROE: 26.43 16.94 16.62

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

09 Nov 2018

Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount

Nov 8 Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

09 Nov 2018

UPDATE 2-Amgen posts higher quarterly EPS, Repatha sales fall short

Oct 30 Amgen Inc on Tuesday said stock buybacks lifted its third-quarter earnings per share, but operating income fell as expenses rose and sales of some key products declined.

31 Oct 2018

Amgen quarterly net profit falls as expenses increase; EPS rises

Oct 30 Amgen Inc on Tuesday said its third quarter profit fell as higher expenses offset a lower tax rate and price concessions kept sales of its cholesterol drug Repatha below Wall Street estimates.

31 Oct 2018

Amgen cuts U.S. price of cholesterol drug Repatha by 60 percent

Amgen Inc , looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the biotechnology company said on Wednesday.

25 Oct 2018

UPDATE 1-Amgen cuts U.S. price of cholesterol drug Repatha by 60 percent

Oct 24 Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the biotechnology company said on Wednesday.

25 Oct 2018

Amgen cuts price of cholesterol drug Repatha by 60 percent

Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

25 Oct 2018

Amgen cuts price of cholesterol drug Repatha by 60 percent

Oct 24 Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

25 Oct 2018

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

LONDON Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States.

16 Oct 2018

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

LONDON, Oct 16 Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States.

16 Oct 2018

Earnings vs. Estimates